Latest Administration News

Echo IQ has formally lodged its FDA 510(k) submission for EchoSolv HF, an AI-driven heart failure diagnostic software validated by Mayo Clinic data, aiming to tap into a $60 billion US market.

Lycopodium Limited has addressed ASX concerns over delayed director interest disclosures, attributing the lapse to an administrative oversight while reaffirming its compliance policies.

Alicanto Minerals has acknowledged a late filing of a director’s interest notice, attributing it to an administrative oversight. The ASX has queried the delay, prompting the company to review its disclosure procedures.

Amplitude Energy has addressed an ASX query regarding the delayed filing of a director’s interest change, attributing it to an administrative oversight while affirming its compliance framework.

An independent meta-analysis presented at the ASH Annual Meeting reveals Mesoblast’s remestemcel-L achieves superior remission rates and safety outcomes compared to ruxolitinib in treating steroid-refractory acute graft-versus-host disease.

Antares Metals has completed the first tranche of a $2 million capital raise, issuing over 128 million shares to support new project acquisitions and ongoing exploration activities.

Elixir Energy Limited has responded to ASX concerns over a delayed director interest disclosure, attributing the lapse to administrative changes and reaffirming its compliance protocols.

Assetora Limited has resolved a recent receivership by fully settling its outstanding debt, bringing external administration to a close within a day.

Aumake Limited has raised $1.5 million through a share placement to strengthen inventory and expand its footprint in China, signaling renewed growth ambitions under a refreshed board.

AKORA Resources has secured strong endorsement from Madagascar’s new government to upgrade its Bekisopa iron ore project licence from exploration to mining, paving the way for project advancement and investment.

Whitefield Industrials Limited has confirmed a fully franked ordinary dividend of AUD 0.105 per share for the half-year ending September 2025, alongside setting the Dividend Reinvestment Plan and Bonus Security Plan issue price at AUD 5.39.

Bioxyne Limited has secured a pioneering manufacturing and supply agreement to enter the emerging medicinal cannabis markets of Costa Rica and Panama, positioning itself as a first mover with promising revenue potential.